Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Domest Anim Endocrinol ; 75: 106595, 2021 04.
Article in English | MEDLINE | ID: mdl-33307335

ABSTRACT

Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. The 300 U/mL (U300) formulation of IGla is associated with longer duration of action and less within-day variability, making it a better basal insulin compared with the 100 U/mL (U100) formulation. We hypothesized that in healthy cats, IGlaU300 has a flatter time-action profile and longer duration of action compared with IGlaU100. Seven healthy neutered male, purpose-bred cats were studied in a randomized, crossover design. Pharmacodynamics of IGlaU100 and IGlaU300 (0.8 U/kg, subcutaneous) were determined by the isoglycemic clamp method. The time-action profile of IGlaU300 was flatter compared with IGlaU100 as demonstrated by lower peak (5.6 ± 1.1 mg/kg/min vs 8.3 ± 1.9 mg/kg/min, respectively; P = 0.04) with no difference in total metabolic effect (ME; P = 0.7) or duration of action (16.8 h ± 4.7 h vs 13.4 h ± 2.6 h; P = 0.2). The greater fraction of ME in the 12- to 24-h period postinjection (35 ± 23% vs 7 ± 8% respectively; P = 0.048) and lower intraday GIR% variability (7.8 ± 3.7% vs 17.4 ± 8.2% respectively; P = 0.03) supports a flatter time-action profile of IGlaU300. There were no differences in onset and end of the action. In summary, although both formulations have a similar duration of action that is well below 24 h, the ME of IGlaU300 is more evenly distributed over a 24 h period in healthy cats, making it a better candidate for once-daily injection in diabetics compared with IGlaU100.


Subject(s)
Hypoglycemic Agents , Insulin, Long-Acting , Animals , Blood Glucose/metabolism , Cats , Cross-Over Studies , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Insulin Glargine/pharmacology , Insulin, Long-Acting/pharmacology , Male
2.
J Neuroendocrinol ; 25(2): 180-9, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22958332

ABSTRACT

The present study aimed to investigate the actions of fibroblast growth factor 21 (FGF21) on energy balance in a natural model of relative fatness, the Siberian hamster. Hamsters were studied under long days (LD) to promote weight gain, or short days to induce weight loss, and treated with rhFGF21 (3 mg/kg/day) via s.c. minipumps for 14 days. On days 7-9, detailed assessments of ingestive behaviour, metabolic gas exchange and locomotor activity were made. FGF21 caused substantial (P < 0.0001) weight loss in the fat LD state but not in the lean SD state: at the end of the study, FGF21-treated hamsters in LD lost 18% of body weight compared to vehicle controls, which is comparable to the natural body weight loss observed in SD. Epididymal fat pads, a correlate of total carcass fat content, were reduced by 19% in FGF21 treated hamsters in LD, whereas no difference was found in SD. Body weight loss in LD was associated with a reduction in food intake (P < 0.001) and a decreased respiratory exchange ratio (P < 0.001), indicating increased fat oxidation. Treatment with FGF21 maintained the normal nocturnal increase in oxygen consumption and carbon dioxide production into the early light phase in hamsters in LD, indicating increased energy expenditure, although locomotor activity was unaffected. These data suggest a greater efficacy of FGF21 in hamsters in LD compared to those in SD, which is consistent with both the peripheral and possibly central actions of FGF21 with respect to promoting a lean phenotype. The observed differences in FGF21 sensitivity may relate to day length-induced changes in adipose tissue mass.


Subject(s)
Adiposity/drug effects , Body Weight/drug effects , Energy Metabolism/drug effects , Fibroblast Growth Factors/pharmacology , Overweight/pathology , Adiposity/genetics , Adiposity/physiology , Animals , Body Weight/genetics , Cricetinae , Eating/drug effects , Eating/physiology , Energy Metabolism/genetics , Fibroblast Growth Factors/physiology , Gene Expression/drug effects , Homeostasis/drug effects , Hypothalamus/drug effects , Hypothalamus/metabolism , Male , Models, Animal , Overweight/genetics , Overweight/metabolism , Phodopus , Photoperiod , Seasons
3.
J Opt Soc Am A ; 2(10): 1644-66, 1985 Oct.
Article in English | MEDLINE | ID: mdl-4056948

ABSTRACT

In this paper we formulate and use information and fidelity criteria to assess image gathering and processing, combining optical design with image-forming and edge-detection algorithms. The optical design of the image-gathering system revolves around the relationship among sampling passband, spatial response, and signal-to-noise ratio (SNR). Our formulations of information, fidelity, and optimal (Wiener) restoration account for the insufficient sampling (i.e., aliasing) common in image gathering as well as for the blurring and noise that conventional formulations account for. Performance analyses and simulations for ordinary optical-design constraints and random scenes indicate that (1) different image-forming algorithms prefer different optical designs; (2) informationally optimized designs maximize the robustness of optimal image restorations and lead to the highest-spatial-frequency channel (relative to the sampling passband) for which edge detection is reliable (if the SNR is sufficiently high); and (3) combining the informationally optimized design with a 3 by 3 lateral-inhibitory image-plane-processing algorithm leads to a spatial-response shape that approximates the optimal edge-detection response of (Marr's model of) human vision and thus reduces the data preprocessing and transmission required for machine vision.


Subject(s)
Vision, Ocular , Visual Perception , Humans , Mathematics , Models, Biological , Models, Psychological , Photography
4.
Appl Opt ; 23(18): 3160, 1984 Sep 15.
Article in English | MEDLINE | ID: mdl-18213140
5.
Appl Opt ; 23(6): 872, 1984 Mar 15.
Article in English | MEDLINE | ID: mdl-18204655
SELECTION OF CITATIONS
SEARCH DETAIL